Brief: Cortexyme’S Atuzaginstat Slowed Cognitive Decline In Participants With Alzheimer’S Disease And P. Gingivalis Infection In Phase 2/3 Gain Trial Additional Top-Line Data Presented At Ctad 2021

IRulya Therapeutics

11/11/2021 17:28

Cortexyme Inc  CRTX.O :
    * CORTEXYME’S ATUZAGINSTAT SLOWED COGNITIVE DECLINE IN
PARTICIPANTS WITH ALZHEIMER’S DISEASE AND P. GINGIVALIS
INFECTION IN PHASE 2/3 GAIN TRIAL: ADDITIONAL TOP-LINE DATA
PRESENTED AT CTAD 2021

Source text for Eikon:  ID:nBw7GJWTxa 
Further company coverage:  CRTX.O